Atopic dermatitis often precedes the development of other atopic diseases. The atopic march describes this temporal relationship in the natural history of atopic diseases.
| INTRODUCTION
The concept of "atopy" (derived from the Greek atopia, meaning "placelessness") was introduced by Coca and Cooke in 1923 to describe the phenomena of allergic hypersensitivity. 1 Atopy is characterized by exaggerated immune responses to allergic stimuli and high
IgE that can lead to clinical disease at a variety of anatomic sites. In general, clinical symptoms of atopy are not present at birth 2 ; however, atopic individuals are predisposed to the development of allergies. For example, the "allergic triad"-atopic dermatitis (eczema), allergic rhinitis, and allergic asthma-frequently presents in a single individual. 3, 4 Other allergic diseases, such as food allergies, eosinophilic esophagitis (EoE), and allergic conjunctivitis, are also common in atopic patients. [5] [6] [7] [8] While allergic symptoms at specific sites often wax and wane over time, the natural history of atopic diseases follows a characteristic sequence of events: The first manifestation of atopy is frequently atopic dermatitis, followed later by food allergy, allergic rhinitis, and allergic asthma. The term "atopic march" (or "allergic march") describes this developmental progression of atopic diseases. The atopic march often begins early in infancy with the development of atopic dermatitis, which peaks in prevalence within the first 2 years of life. 9 Of the children who develop atopic dermatitis, many, if not most, develop the disease within the first 6 months of life. 9, 10 The age at which food allergies present varies depending upon the allergen; allergies to hen's egg and cow's milk generally develop within the first year of life, whereas allergies to wheat, soy, and peanut tend to develop later in childhood. 11 The prevalence of allergic rhinitis continues to rise from early childhood into adolescence. 12 Although asthma has substantial heterogeneity that likely represents distinct pathophysiological mechanisms, individuals with chronic asthma often present before the age of five. [13] [14] [15] Children with atopic dermatitis are more likely to develop other atopic diseases than those without atopic dermatitis. [16] [17] [18] [19] Furthermore, the severity and chronicity of atopic dermatitis also correlate with increased incidence of atopic diseases. 16, 17, 20 Whereas around 20% of children with mild atopic dermatitis develop asthma, over 60% with severe atopic dermatitis develop asthma. 21, 22 A recent systematic review of studies that examined the relationship between atopic dermatitis and food allergies noted sixfold higher odds of food
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sensitization in children with atopic dermatitis than in healthy controls as well as positive correlations between food allergy and the age of onset, severity, and chronicity of atopic dermatitis. 17 Although the mechanisms that underlie the temporal relationship of diseases in the atopic march are still poorly understood, epidemiological studies have provided a framework for experimental models to examine how atopic dermatitis and skin barrier dysfunction can lead to disease at other anatomic sites. We present here a review of factors that affect the development of atopic diseases and the atopic march with a focus on the role of skin barrier dysfunction and epithelial cellderived cytokines. We conclude with a discussion of approaches to prevent development of the atopic march and how epithelial cellderived cytokines may represent a new therapeutic target for the prevention of the atopic march and treatment of atopic diseases.
| ENVIRONMENTAL FACTORS IN ATOPIC DISEASE DEVELOPMENT
Over the last century, there has been a rapid rise in atopic disease incidence, particularly in more industrialized countries. [23] [24] [25] [26] This increase in atopic diseases has led to the proposal of the "hygiene hypothesis,"
which suggests that early infectious or microbial exposures may play a protective role against the development of atopic diseases. A wide variety of lifestyle and environmental changes are thought to have contributed to changes in childhood infectious and microbial exposures. In 1989, Strachan noted an inverse relationship between the subject's number of siblings and the rate of allergic disease in those individuals. He proposed that fewer older siblings, improvements in household amenities, and higher standards of personal cleanliness resulted in decreased cross-infection that subsequently led to increases in clinical manifestations of allergic disease. 27 Other studies have also supported a correlation between family size and atopic disease prevalence, at least in more affluent populations. [28] [29] [30] In less industrialized nations, the frequency of atopic diseases appears to be higher in more affluent communities than in less affluent ones and higher in urban areas than in rural areas. [31] [32] [33] [34] [35] Some studies have suggested that exposure to helminths may be protective in these less affluent, more rural communities. 31, 35, 36 The strongest epidemiological data for the hygiene hypothesis in atopic disease development may be the results from studies of children who have grown up on farms. Whereas some data support a positive correlation between nasal colonization with certain types of bacteria and risk for recurrent wheeze and asthma early in life, 37 increasing numbers of studies now show that growing up on farms, which generally correlates with increased microbial exposure, is protective against the development of asthma. [38] [39] [40] A recent study in the United States examined asthma and allergic sensitization in Amish communities that follow traditional farming practices and Hutterites that follow industrialized farming practices. 39 Although these communities share a common genetic ancestry, the Amish had a lower prevalence of asthma and allergic sensitization than the Hutterites. Median levels of endotoxin were also significantly higher in the Amish community.
Our understanding of how infectious or microbial exposures affect atopic disease risk remains limited, but several studies suggest that these exposures may "tolerize" the immune system through effects on both the innate immune system and adaptive immune system. In the study by Stein and colleagues, immune profiling and gene expression analyses suggested that modulation of the innate immune system was an important underlying mechanism that correlated with protection against allergic diseases in the Amish population. 39 Maternal farm exposure during pregnancy can skew early immune development of the fetus toward an allergy-protective status that is potentially mediated by Th1 or regulatory T (Treg) cells. 41 Childhood exposures to microbial products can also regulate epithelial response to allergens. 40 Thus, this immune modulation may occur during pregnancy or as early-life exposures.
| THE GENETICS OF ATOPIC DISEASES AND THE ATOPIC MARCH
While changes in environmental exposures provide some potential as targeted means of decreasing the prevalence of atopic disease, there is a strong influence of genetics on the development of allergies. Based primarily on twin studies of asthma and atopic dermatitis, the heritability of atopic diseases has been estimated to be around 60%-75%.
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| Epithelial defects and the genetics of atopic diseases
Genetic studies have provided evidence of the importance of epithelial barrier defects in the pathophysiology of atopic dermatitis and other atopic diseases. In particular, mutations in genes encoding three important components of the epithelial barrier of the skin-filaggrin, serine peptidase inhibitor Kazal-type 5 (SPINK5), and corneodesmosin-are associated with atopic dermatitis or atopic dermatitis-like syndromes as well as atopic diseases at other sites.
Filaggrin is expressed as the precursor protein profilaggrin that is subsequently cleaved into filaggrin, which then aggregates and organizes keratin filaments within the skin epithelium. Mutations in the gene encoding filaggrin (FLG) can give rise to ichthyosis vulgaris and lead to an increased susceptibility to atopic dermatitis. 45, 46 Filaggrin loss-of-function mutations have been shown to be associated with increased risk of food allergy and eosinophilic esophagitis. 47, 48 Some studies have also reported increased risk of asthma or increased asthma severity with these filaggrin mutations, but it is unclear whether this effect on asthma incidence or severity was dependent on having coincident atopic dermatitis.
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Netherton syndrome is a severe, autosomal recessive disorder caused by mutations in the SPINK5 gene, which encodes serine protease inhibitor Kazal-type 5 (also referred to as lympho-epithelial Kazaltype-related inhibitor [LEKTI]). 52, 53 At the neutral pH of the deep stratum corneum, LEKTI binds and inhibits the proteases kallikreinrelated peptidase 5 (KLK5) and KLK7; in the acidic conditions of the upper stratum corneum, LEKTI is inhibited, which allows KLK5 and KLK7 to function and promote skin peeling. 54 In Netherton syndrome, LEKTI deficiency allows for KLK5 and KLK7 proteolytic activity even in the deeper levels of the skin. Infants and children with this syndrome develop a severe atopic dermatitis-like syndrome and a specific hair shaft defect (trichorrhexis invaginata or "bamboo hair"). 55 Netherton syndrome patients also have other atopic manifestations including hay fever, food allergies, high serum IgE levels, and hypereosinophilia. 52, 56, 57 Another 
| The genetics of the atopic march
As discussed earlier, mutations in the filaggrin gene are strongly associated with risk for atopic dermatitis but have also been associated with risk for food allergies and asthma. Additional support for a central role of the epithelium in the pathogenesis of allergic diseases is provided by variants of genes encoding epithelial cell-derived cytokines and their receptors that confer increased risk of allergic disease.
Single nucleotide polymorphisms (SNP) at the loci for thymic stromal lymphopoietin (TSLP) or its receptor have been implicated in risk for asthma, atopic dermatitis, and eosinophilic esophagitis [66] [67] [68] [69] ; SNPs in the loci for IL-33 or its receptor are associated with risk for asthma and atopic dermatitis. [70] [71] [72] A large number of studies have now been performed examining the genetics of individual atopic diseases. In a large genomewide association study (GWAS) of asthma conducted by the GABRIEL consortium, IL-18R1, IL-33, IL-1RL1 (encoding the IL-33 receptor), SMAD3
(a transcriptional regulator activated by TGF-β signaling), ORMDL3, HLA-DQ, and IL-2RB loci were all significantly associated with asthma. 72 In the GABRIEL consortium study, the ORMDL3/GSDMB locus was found to be specific to child-onset asthma. Although some genetic susceptibility loci seem specific to certain atopic diseases, the numerous loci associated with both atopic dermatitis and asthma suggest shared underlying pathways. Of note, the genetics of atopic dermatitis has highlighted the importance of the skin barrier. The increased susceptibility to allergic diseases at multiple anatomic sites seen in individuals with filaggrin, SPINK5, and CDSN mutations also suggests a pathophysiological or mechanistic link between skin barrier defects and increased risk of atopic disease at other sites.
| SKIN SENSITIZATION AND THE ATOPIC MARCH
How early can sensitization begin, and what is the role of the skin as a site of sensitization in the development of the atopic march? As a means of determining when sensitization takes place, most studies have used IgE as a serologic marker of sensitization. IgE antibodies of fetal origin can be generated as early as the 11th week of gestation. 9, 16, 77 However, in a large, population-based birth cohort study, peanut-specific IgE was not detected in cord blood samples, even in samples from children who subsequently developed peanut sensitization or allergy. 16 The first IgE responses to food proteins generally developed during the first months of life, peaked in prevalence at around 10% at 1 year of age, and then decreased to 3% by 6 years of age. 9, 11, 16 Although high levels of hen's egg-specific IgE can sometimes be detected in infants that are completely breast-fed, this is likely to be through the transfer of maternal IgE from the mother's milk. 78 Whether this transfer of maternal IgE may promote allergic disease development or tolerance remains unclear. 79 Sensitization to inhalant allergens generally develops after infancy.
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Although it is difficult to establish directly the frequency to which sensitization occurs through the skin, the observation that atopic dermatitis tends to precede atopic disease at other sites has led to the proposal that the skin may be an important site in the initiation of the atopic march. In fact, even in the absence of atopic dermatitis, children with skin barrier defects are still at a higher risk for asthma than healthy children, suggesting that the skin may serve as a site for sensitization to allergens even when allergic skin inflammation is absent. 16 In asthma, the distribution of allergens within the environment typically can result in both skin and lung exposures and thus may preclude the study of routes of sensitization. However, some occupational exposures that likely occur through the skin, such as exposure to isocyanates, can increase asthma risk. 80 In chronic beryllium disease, an occupational lung disease, beryllium can penetrate the skin, and both skin and lung exposures have been suggested as routes of beryllium sensitization in the workplace. [81] [82] [83] [84] There is certainly considerable heterogeneity in asthma, and the underlying pathophysiology of childhood allergic asthma and occupational asthma is distinct.
However, these occupational exposures provide at least some data to suggest that the skin may be a site of sensitization for subsequent development of asthma.
Several studies have been able to link skin allergen exposure to increased risk of food allergies to those allergens. A case-control study in Japan showed that use of a wheat-containing facial soap was positively correlated with development of food allergy to wheat. 85 In the Avon Longitudinal Study of Parents and Children, skin sensitization was also linked to food allergy by demonstrating that application of peanut oil to inflamed skin was positively associated with the development of peanut food allergies. 16 In this study, maternal consumption of peanuts during pregnancy was not associated with the development of food allergies in the child, and peanut-specific IgE was not detectable in cord blood, suggesting that sensitization to food antigens did not occur in utero. Furthermore, levels of peanut allergens found in breast milk were also not associated with sensitization.
Additional insights into where allergic sensitization takes place have come from the analysis of allergen-specific T cells that become "imprinted" and express specific patterns of homing molecules based on where they are activated and differentiate. In peanut-allergic patients, peanut allergen Ara h 1-specific T cells expressing a memory phenotype also expressed CCR4, a Th2-associated cell trafficking marker. 86 In another study, memory T cells from peanut-allergic subjects that expressed the skin-homing marker cutaneous lymphocyte antigen (CLA) showed increased proliferation compared with those that expressed α4β7 integrin, a gastrointestinal-homing marker. 87 These data suggest that in peanut allergy, allergic sensitization may occur through the skin.
In addition to allergen exposure, sensitization usually requires the presence of other factors that may function as adjuvants: exogenous adjuvants, bacteria colonization of lesional skin, allergens with intrinsic protease activity, or skin barrier damage or defects. 88 Most if not all of these factors elicit the production of cytokines, notably TSLP, interleukin-33 (IL-33), and interleukin-25 (IL-25) from the epithelium.
| ANIMAL MODELS OF ATOPIC DISEASES
| Models of atopic dermatitis and skin barrier dysfunction
Several animal models have now been developed to begin to dissect the role of candidate genes in skin barrier function. Spink5 deficiency in mice resulted in perinatal or early postnatal death. 89, 90 Similar to the epithelium from individuals with Netherton syndrome, the skin of Spink5 −/− mice had abnormal keratinization and detachment of the stratum corneum from the underlying layer of the skin. Loss of LEKTI activity resulted in elevated proteolytic activity, destabilization of desmosomes, and dysregulated processing of corneodesmosin. [89] [90] [91] Mice lacking corneodesmosin also had early postnatal lethality and showed detachment of the stratum corneum from the underlying layer. 92, 93 Loss of corneodesmosin in adulthood using a skin-specific, inducible CDSN knockout resulted in a severe skin phenotype that ultimately required euthanasia of these mice. 93 "Flaky tail" mice have a frameshift mutation in the filaggrin gene that is analogous to common human FLG mutations and resulted in an almost complete loss of processed filaggrin. 94 Flaky tail mice appeared normal at birth, but as neonates, they developed dry, flaky skin, shortened ears, and tail constrictions that sometimes resulted in autoamputation. [95] [96] [97] There was then a gradual improvement of phenotype, and flaky tail mice appeared normal by 2-3 weeks of age. 97 Topical application of a model allergen to intact skin of flaky tail mice was sufficient to induce cutaneous inflammatory infiltrates, allergen-specific IgE, and cytokine responses similar to those seen in human atopic dermatitis. 94, 98 Although initial studies did not demonstrate lung inflammation after subsequent pulmonary challenge, 94 other studies have shown an IL-33-mediated eosinophilic esophagitis after intranasal antigen challenge of sensitized flaky tail mice. 
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Unlike the model antigen OVA, allergens that have intrinsic protease activity can induce sensitization when applied to healthy intact skin. A primary example of this is peanut. 106 After epicutaneous exposure to peanut protein, a single oral antigen challenge can induce anaphylaxis. 107 Application of Ara h2, the dominant allergen in peanut, is in fact sufficient to induce IgE production, anaphylaxis, and sensitization. 106 Subsequent studies that use these methods of skin sensitization have examined the cytokine pathways and cellular requirements of allergen sensitization and challenge. 
| EPITHELIAL CELL-DERIVED CYTOKINES AND THE ATOPIC MARCH
| Thymic stromal lymphopoietin (TSLP)
Murine TSLP was initially discovered as a thymic stromal cell linederived growth factor that supported immature B-cell proliferation and development. 108, 109 Subsequently, a human homolog was identified using in silico methods. 
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TSLP is expressed at basal levels in the lung, tonsils, and intestines 126, 127 . 128 Its expression can be further enhanced through exposure to viral, bacterial, or parasitic pathogens as well as TLR agonists. 129 Although TSLP expression was undetectable in normal skin, it was found to be highly expressed in the lesional skin of individuals with atopic dermatitis, 130 in skin biopsies from patients with peeling skin syndrome type B, 131 and in the airways of asthmatics. 132 TSLP levels in asthmatic airways correlated with Th2-attracting chemokine expression and disease severity. 132 In eosinophilic esophagitis, a gainof-function polymorphism in TSLP is associated with disease in pediatric subjects, 66, 67 and TSLP expression was higher in esophageal biopsy samples from children with active EoE than in biopsy samples from control subjects or subjects with inactive EoE. 133 Skin-specific overexpression of TSLP under a keratinocyte-specific promoter resulted in a spontaneous atopic dermatitis-like phenotype. 134 Keratinocyte-specific deletion of components of Notch signaling led to high levels of TSLP released into systemic circulation. 135 In mouse models of skin sensitization, TSLP is induced following tape stripping or topical application of MC903 (a low calcemic analogue of vitamin D3). Skin sensitization in these models drives local skin inflammation that resembles atopic dermatitis. Both TSLP and basophils have been shown to be important in this model, as disease is attenuated in TSLPR knockout mice and in diphtheria toxin (DT)-treated, basophil-depleted Baso-DTR mice. 136 Accumulation of basophils in the skin following MC903 treatment was TSLP dependent and IL-3 independent. 137 After sensitization with MC903, antigen challenge in the lung aggravated airway inflammation, 138, 139 whereas antigen challenge orally drove esophageal inflammation and eosinophilia or intestinal food allergy. 136 In the food allergy model, OVA treatment without MC903 but with concurrent transfer of TSLP-elicited basophils could drive disease upon oral challenge with antigen. TSLP is also involved in disease at challenge, as treatment with TSLP-specific antibody after sensitization significantly decreased eosinophilia and inflammation in the esophagus, even in established eosinophilic esophagitis. 133 We have developed a model of the atopic march in which skin sensitization is induced through intradermal injection of TSLP in the presence of antigen. 104 Unlike with tape stripping and MC903 treatment, circulating levels of TSLP were not detectable after intradermal injection. After skin sensitization, intranasal antigen challenge promoted airway inflammation, 104 and oral antigen challenge drove allergic diarrheal disease. 105 In the food allergy model, DC-intrinsic TSLP signaling was required to control antigen-specific type 2 responses, as loss of TSLP signaling specifically in DCs led to loss of TSLP-induced allergic diarrhea. 105 Diarrheal disease was also attenuated after basophil depletion, either through treatment with Ba103, a monoclonal antibody that binds the activating receptor CD200R3 on basophils and mast cells, or through DT treatment of Mcpt8-DTR transgenic mice. 105 
| Interleukin-33 (IL-33)
ST2 (suppression of tumorigenicity 2; also known as IL-1RL1, T1, and IL-33R), the receptor for IL-33, was identified almost three decades ago, 140 yet it remained an orphan receptor until the identification of 164 In the peanut allergy model, DCs from the skin-draining lymph nodes of mice treated with anti-ST2 were shown to have decreased ability to prime T cells in vitro compared to DCs from isotype control-treated mice. 106 Skin-specific overexpression of IL-33 can drive spontaneous dermatitis in mice, which is associated with ILC2 infiltration. 165 In addi- Unexpectedly, this antibody specifically prevented AHR even during an ongoing type 2 inflammatory response in the lungs. 188 This approach
has not yet been studied in asthmatic patients. It is interesting to note that unlike TSLP and IL-33, intradermal administration of IL-25 plus antigen followed by antigen challenge was not able to promote disease in models of experimental asthma 104 167 In a model of chronic HDM exposure, IL-33 mRNA levels were elevated at early and late time points, whereas TSLP mRNA was only upregulated at early time points, and IL-25 mRNA was upregulated only at late time points. 190 Reporter mice for TSLP, 191 IL-25, 176 and IL-33 157 may help define the cell-type-specific expression kinetics of these cytokines.
Models of allergic inflammation have shown distinct requirements
for TSLP, IL-33, and IL-25. After mice were exposed to intranasal HDM or intragastric peanut, IL-33 but not TSLP or IL-25 was required to drive inflammation. 192 In these models, IL-33 induced a robust induction of OX40L expression on DCs and expansion of ILCs. Consistent with the findings by Chu and colleagues, IL-33 but not IL-25 was found to be required for airway hyperreactivity after intranasal ragweed challenge, which robustly increased the expression of IL-33, but not IL-25, and expanded IL-13-producing ILC2 in the lung. 162 We have found that the TSLP-TSLPR axis is not required in IL-33-driven food allergy; in contrast, mice lacking ST2 or IL-17RB had attenuated disease in TSLPdriven food allergy 105 Although the roles of TSLP, IL-33, and IL-25 are clearly distinct and influenced by a variety of factors, the underlying mechanisms driving these differences and how these cytokines may interact remain poorly defined. Recent work has suggested that DCs and basophils cooperate to promote Th2 differentiation, but that the relative contributions of these two cell types to allergic inflammation may be distinct depending on the stimuli. Otsuka et al. 195 found that basophils drove Th2 differentiation following epicutaneous sensitization with hapten or peptide antigens but not with protein antigens. We found that type 2 sensitization using the hapten FITC with dibutyl phthalate (DBP) required TSLP-responsive DCs but that basophils were not involved. 196 In type 2 immunity after HDM inhalation, DCs but not basophils have been shown to be required. 197 
| CAN THE ATOPIC MARCH BE HALTED?
| Early interventions to halt the atopic march
Treatment and prevention strategies in infants and young children with atopic dermatitis are targeted toward treating the symptoms of atopic dermatitis, restoring skin barrier functions, and reducing the absorption of environmental allergens to attempt to attenuate or block the onset of asthma and food allergy. Given that the initiating events in atopic dermatitis remain poorly understood, identifying those at risk and implementing strategies to prevent atopic dermatitis might be impractical. However, the use of emollients soon after birth (before the onset of atopic dermatitis) can reduce the incidence of atopic dermatitis, 199, 200 and thus may represent an inexpensive, easy to apply, safe, and effective approach for atopic dermatitis prevention. Maternal diet has not been shown to play a role in sensitization; thus, dietary restrictions are not recommended for pregnant or lactating mothers. 201 It is unclear whether the use of anti-inflammatory agents to control atopic dermatitis might be beneficial in decreasing subsequent development of asthma or food allergy.
Several studies have suggested that antihistamine therapy can decrease the risk of subsequent development of asthma in infants with atopic dermatitis, at least in specific risk groups. In infants at high risk of developing asthma, such as those with atopic dermatitis or family history of major allergies plus high IgE, subjects treated with ketotifen, an H1 antihistamine, had a significantly lower frequency of asthma at follow-up than control subjects. 202, 203 In infants with atopic dermatitis, early treatment with cetirizine (initiated between one and 2 years of age) did not show a difference in the development of asthma between cetirizine and placebo in the intention-totreat population; however, the incidence of asthma was significantly reduced in the subgroups sensitized to grass pollen or house dust mite. 204 Although there was a gradual narrowing of the difference in asthma incidence between cetirizine treatment and placebo in the house dust mite-sensitized group, grass pollen-sensitized individuals treated with cetirizine continued to have a lower incidence of asthma than the placebo group up to 18 months after cetirizine treatment stopped. 205 Thus, cetirizine may delay or prevent asthma onset, particularly in a subgroup of grass pollen-sensitized children with atopic dermatitis.
| Allergen-specific immunotherapy and tolerance
Subcutaneous allergen-specific immunotherapy (SCIT) has been used in clinical practice for over a century and has efficacy in allergic rhinitis, rhinoconjunctivitis, asthma, and hymenoptera venom allergies. [206] [207] [208] However, SCIT requires repeated injections and carries a risk for anaphylaxis. In particular, initial trials of desensitization to food allergy through SCIT had unacceptably high rates of systemic reactions. 209 To increase ease of use and minimize side effects while improving efficacy, other routes for allergen-specific immunotherapy have been studied, including epicutaneous immunotherapy (EPIT), sublingual immunotherapy (SLIT), and oral immunotherapy (OIT). The approach to therapy is the same regardless of the route-increasing doses of allergen are administered gradually with the goal of establishing desensitization and "immune tolerance". [210] [211] [212] Allergen-specific immunotherapy has been shown to modify the immune response in several ways that correlate with clinical tolerance to antigen, including suppression of mast cell and basophil degranulation, induction of regulatory T and B cells, and elevation of IgG4 levels. 213 It is interesting to note that decreases in IgE levels are not required for improvements in clinical symptoms. Recent studies of OIT have demonstrated efficacy in desensitization for food allergy with similar immunologic changes as those seen for SLIT and SCIT. 214, 215 Tolerance to peanut after oral immunotherapy correlated with regulatory T-cell induction and epigenetic changes in the FOXP3 locus. 212 Single-cell gene expression analysis of individual CD4 + T cells throughout oral immunotherapy in a cohort of peanutallergic subjects also demonstrated an expansion and shift of peanutspecific CD4 + T cells toward an "anergic" Th2 T-cell phenotype. 215 Antigen-specific IgG antibodies were also increased after peanut immunotherapy and inhibited FcεRI-mediated basophil activation in a FcγRIIb-dependent manner. 216 Although earlier guidelines have recommended delayed introduction of certain foods in infants at high risk for atopic disease, 217 evolving concepts of oral tolerance and subsequent studies correlating early consumption of peanut, cow's milk, and egg with lower prevalence of food allergies have led to changing views on food consumption in infancy and the risk of atopic disease. 218 The Learning Early About Peanut Allergy (LEAP) trial was designed to assess whether early introduction of peanut during infancy, rather than avoidance, prevented the development of peanut allergy. In high-risk atopic infants, sustained peanut consumption dramatically decreased the frequency of the development of peanut allergy at 60 months of age compared with children who completely avoided peanut. 219 In a follow-up trial, subjects who consumed peanuts early in life then avoided peanuts for 12 months continued to have a lower prevalence of peanut allergy than those who avoided peanuts. 220 Initial population-based studies suggest that early introduction of other foods associated with food allergies, such as cow's milk, may also be effective in promoting tolerance in high-risk infants. 221 On the basis of these studies, interim international consensus guidelines were issued to highlight early introduction of peanut in high-risk infants as a primary preventive strategy. 222 In a trial of breast-fed infants who were not necessarily at high risk for atopic disease, early introduction of six allergenic foods (peanut, cooked egg, cow's milk, sesame, whitefish, and wheat) was shown to be safe. 223 Although the intention-to-treat analysis did not reach significance, the prevalence of peanut allergy and egg allergy was significantly lower in the early-introduction group than in the standardintroduction group in per-protocol analyses. Thus, approaches to promoting tolerance in allergy have shown promising results but require further study.
| Epithelial cell-derived cytokines as new therapeutic targets
In recent years, biological therapies have been developed that more specifically target the allergic immune response. Omalizumab is a humanized anti-IgE monoclonal antibody that prevents the binding of IgE to Fc receptors on basophils and mast cells and was the first biological treatment approved for the treatment of allergic asthma. 224 Although omalizumab is not FDA-approved for allergic rhinitis, it has shown some efficacy in the treatment of both seasonal and perennial allergic rhinitis. 225 Initial food allergy treatment studies have shown that the addition of omalizumab to OIT may improve safety, although efficacy may be comparable to OIT alone. 226, 227 Therapeutic blockade of type 2 effector cytokines such as IL-4, IL-5, IL-9, and IL-13 has now also been examined in clinical trials, and the results from some of these studies have been promising. 228 Additional studies are needed to establish the efficacy and durability of therapeutic responses after treatment with these cytokine-blocking antibodies.
The targeting of epithelial cell-derived cytokines such as TSLP, IL-25, and IL-33 has emerged as a novel therapeutic strategy in allergic 
| CONCLUSION
The development of atopic dermatitis early in life predisposes children to subsequent development of food allergy, allergic rhinitis, and asthma-a phenomenon known as the "atopic march." Data from epidemiological studies and animal models suggest that skin barrier defects that allow increased exposure and sensitization to allergens may be important factors in the march from allergic skin inflammation to disease at other sites. It is increasingly apparent that the epithelium at barrier sites is not only a protective lining but is also an important source of cytokines such as TSLP, IL-33, and IL-25 that may initiate and drive type 2 inflammation at these sites. Further studies are needed to clarify the specific roles of these cytokines in the atopic march. While some level of redundancy exists, animal models have demonstrated that TSLP, IL-33, and IL-25 do play distinct roles in allergic inflammation. The requirements for these epithelial cytokines in both the initiation and maintenance of inflammation make them attractive targets for therapy.
